Trials / Available

AvailableNCT04710056

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

Status: Available
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: Regeneron Pharmaceuticals · Industry
Sex: All
Age: —
Healthy volunteers: —

Summary

Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.

Detailed description

Expanded Access requests are only being considered in response to Individual Patient and Intermediate-Size Population EAP Investigational New Drug (IND) applications. Availability will depend on location.

Conditions

Lipodystrophy
Generalized Lipodystrophy (GLD)
Monogenic Obesity (MOB)

Interventions

Type	Name	Description
DRUG	REGN4461	To be provided by Regeneron

Timeline

First posted: 2021-01-14
Last updated: 2026-03-12

Source: ClinicalTrials.gov record NCT04710056. Inclusion in this directory is not an endorsement.